CDMO Samsung Biologics telegraphs spinoff of biosim unit
Samsung Biologics will devote itself fully to contract manufacturing under a plan to spin off a new investment holding company that will oversee the drugmaker’s biosimilar subsidiary Samsung Bioepis. Samsung Bio attributed the decision to industry concerns about conflicts-of-interest between its CDMO and biosimilar development businesses.
Samsung Biologics will devote itself fully to contract manufacturing under a plan to spin off a new investment holding company that will oversee the drugmaker’s biosimilar subsidiary Samsung Bioepis. Samsung Bio attributed the decision to industry concerns about conflicts-of-interest between its CDMO and biosimilar development businesses.
